Navigation Links
CorMedix Granted Extension of NYSE MKT Listing
Date:7/15/2013

BRIDGEWATER, N.J., July 15, 2013 /PRNewswire/ -- CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, received a notice from the NYSE MKT that the NYSE MKT has granted CorMedix an extension until October 20, 2013 to regain compliance with the continued listing standards of the NYSE MKT.

CorMedix had received notice on April 20, 2012 from the NYSE MKT informing it that CorMedix was not in compliance with Section 1003(a)(iv) of the NYSE MKT's continued listing standards due to financial impairment.  CorMedix was afforded the opportunity to submit a plan to the NYSE MKT to regain compliance and, on May 17, 2012, presented its plan to the NYSE MKT.  On June 27, 2012, the NYSE MKT accepted CorMedix's plan and granted it an extension until August 22, 2012 to regain compliance with the continued listing standards. On September 21, 2012, the NYSE MKT notified CorMedix that it granted CorMedix another extension to January 31, 2013 and on February 1, 2013, NYSE MKT notified that CorMedix was further granted extension until April 15, 2013 to regain compliance with the continued listing standards of the NYSE MKT. By letter dated July 9, 2013, the NYSE MKT notified CorMedix that it has been granted an additional extension until October 20, 2013.

Separately, and as previously reported, on April 5, 2013, CorMedix received notice from the NYSE MKT indicating that CorMedix was not in compliance with Section 1003(a)(i) of the NYSE MKT's continued listing standards due to having less than $2 million of stockholders' equity as reported in its Form 10-K for the fiscal year ended December 31, 2012. On May 6, 2013, CorMedix submitted a plan of compliance to the NYSE MKT setting forth our plan to regain compliance with the NYSE MKT listing standards by October 20, 2013. On May 29, 2013, the NYSE MKT notified CorMedix that it was granted an extension until October 20, 2013 to regain compliance with the Section 1003(a)(i) of the NYSE MKT listing standards. 

If CorMedix is not in compliance with all of the NYSE MKT's continued listing standards by October 20, 2013, the NYSE MKT will initiate delisting proceedings. Under the rules of the NYSE Company Guide, CorMedix is allotted a maximum of 18 months from the date of a deficiency letter to regain compliance with listing standards.  Accordingly, CorMedix will not be eligible for an extension beyond October 20, 2013.

About CorMedix                                                               

CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease.  CorMedix's most advanced product candidate is CRMD003 (Neutrolin®) for the prevention of catheter-related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Please see www.cormedix.com for additional information.

Forward-LookingStatements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: CorMedix's ability to maintain its listing on the NYSE MKT; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates; the outcome of clinical trials of CorMedix's product candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources, obtaining additional financing to support CorMedix's research and development and clinical activities and operations; CorMedix's ability to enter into and maintain collaborations with third parties for its development programs; CorMedix's dependence on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations; CorMedix's dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

(Logo: http://photos.prnewswire.com/prnh/20130715/NY47431LOGO )


'/>"/>
SOURCE CorMedix Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Granted US Patent On Hybrid Opioids
2. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
3. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
4. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
5. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
6. Cedarburg Hauser Granted DEA Registration for Denver Manufacturing Facility
7. KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101
8. US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
9. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
10. Harvest Technologies Corporation Granted CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia
11. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...   Bernstein Liebhard LLP today announced that a ... District Court for the District of Arizona ... all persons or entities who purchased common shares of Insys ... from March 3, 2015 through January 25, 2016 (the "Class ... with violations of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 2016  Montoya Love is recognized by Continental Who,s ... Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range ... provides healthcare institutions, clinical laboratories and life science researchers ... the globe. ...
(Date:2/4/2016)... -- Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) ... Chronic Obstructive Pulmonary Disease (COPD) is a ... airways and lungs. Persistent breathing difficulties and repeated ... of the leading causes of morbidity and the ... is linked to cumulative exposure to risk factors, ...
Breaking Medicine Technology:
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced ... with the tools and information to lower the costs, and increase the impact ... of providing employee healthcare benefits by as much as 22%:, + Price ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... ... phases of eating disorder treatment helps to reduce the frequency and level of ... the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks ...
(Date:2/5/2016)... NY (PRWEB) , ... February 05, 2016 , ... Love ... long-stem roses in a variety of colors, assortments and packaging. This staple for Valentine’s ... any King Kullen location. , For Valentine’s Day, not only are long-stem roses ...
Breaking Medicine News(10 mins):